NeuroReality

NeuroReality operates at the intersection of digital health, neuroscience, and immersive technology, with Koji’s Quest focused specifically on cognitive rehabilitation and brain training. Its approach combines VR exercises informed by neuroscience with game mechanics, adaptive difficulty, and options for clinical or home use. Website information describes gaze-based controls and performance tracking, while the company’s overview presents the product as a way to connect patients, clinicians, and other stakeholders. A relevant market reference is XRHealth: it added NeuroReality cognitive training to its virtual clinics in 2022 and acquired NeuroReality in November 2024. That relationship places Koji’s Quest within a broader XR therapeutic offering, rather than establishing a head-to-head competitive position. Its stated CE marking as a Class I medical device under MDD and availability in five languages are meaningful product attributes, but do not by themselves establish comparative clinical efficacy, market share, or regulatory status in other jurisdictions.

NeuroReality’s growth path appears to have moved from early product development toward integration with a larger therapeutic XR business. Founded in 2017, the company raised a €800,000 pre-seed round—approximately $959,296—on May 1, 2018, with Rising Stars as lead investor. By Sep 7, 2022, XRHealth was adding NeuroReality cognitive training to its virtual clinics, providing evidence of an early distribution or product-integration relationship. The most significant inflection point was XRHealth’s acquisition of NeuroReality, announced on Nov 6, 2024. The company is associated with a small employee band of 1–10, and no hiring news or layoffs are reported. Overall, the available milestones show product development, platform integration, and acquisition, but do not establish post-acquisition growth in users, staffing, revenue, or clinical outcomes.